Novartis has got approval from the US health regulator for its heart failure treatment tablets- LCZ696 and now the company is planning to launch the medicine.
Early approval by the USFDA, ahead of priority review date of LCZ696, will benefit many patients afflicted with heart failure, says Novartis India Country President Ranjit Shahani.
“Novartis India is working hard to bring this important treatment to Indian patients in a timely way,” he said.
The company is planning to launch LCZ696 (sacubitril/valsartan) tablets under ‘Entresto’ brand name in the US market.
